What Is Considered Long-Term Use of Tramadol?

Most clinical research defines long-term tramadol use as continuous or cumulative use lasting 90 days or more. That threshold appears repeatedly across studies examining the drug’s risks, from persistent prescribing after surgery to hormone disruption and organ damage. Some researchers use lower cutoffs of 30 days to distinguish short-term from intermediate exposure, but 90 days is where the most serious health concerns start to cluster. The picture gets more complicated when you consider that tramadol’s dual mechanism makes its long-term effects unlike those of a typical opioid.

Where the 90-Day Threshold Comes From

There is no single, universally agreed-upon definition of “long-term” tramadol use, but the research community has largely converged on 90 days as the boundary that matters. A large cohort study published in the BMJ used three overlapping definitions of prolonged opioid use after surgery, all anchored around the 90-day mark: at least one opioid fill 90 to 180 days after surgery, any span of use starting within 180 days that lasts 90 days or longer, and a stricter version requiring 90 or more days with either 10 or more prescription fills or 120 days’ supply.¹ A retrospective cohort study on tramadol and depression risk categorized users into tiers of 1 to 29 days, 30 to 89 days, and 90 days or more of cumulative prescription over a five-year period.²

The practical takeaway is that if you have been taking tramadol most days for three months or longer, clinical research would classify your use as long-term. If you have been taking it for one to three months, you are in a gray zone where some risks are beginning to accumulate, but the data on serious outcomes is thinner. Under 30 days is generally considered short-term or acute use.

Why Tramadol Is Not a Typical Opioid

Understanding what makes long-term tramadol use distinctive requires knowing that it does not work like most painkillers. Tramadol is a centrally acting synthetic painkiller with a dual mechanism: it activates opioid receptors in the brain (the same ones targeted by morphine or oxycodone) and it also blocks the reuptake of serotonin and norepinephrine, two chemicals more commonly associated with antidepressants.³ This combination means tramadol sits in an awkward category. It is weaker at the opioid receptor than drugs like morphine but carries an additional set of risks that come from its antidepressant-like activity.⁴

That dual action has practical consequences. When you stop tramadol after extended use, you can experience not just the typical opioid withdrawal symptoms people might expect but also a second layer of symptoms tied to the serotonin and norepinephrine system. This makes long-term tramadol use a different beast from long-term use of a pure opioid, both in how dependence develops and in how difficult it can be to quit.

How Dependence Builds Over Time

Early animal studies painted tramadol as relatively benign compared to morphine. In mice, chronic tramadol administration did not produce the same tolerance pattern seen with morphine, and physical dependence signs were absent even after sustained dosing, a finding attributed to the drug’s non-opioid mechanisms contributing to pain relief without the same neural adaptation.⁵ That early optimism shaped how tramadol was initially marketed and perceived: as an opioid that was unlikely to cause dependence.

Human data tells a less reassuring story, especially at higher doses. A controlled study in human volunteers found that the development of physical dependence from tramadol appears dose-related, and that administration of 800 mg per day produced opioid physical dependence comparable to 60 mg per day of morphine.⁶ The same study noted that while acute doses may not produce pronounced opioid-like effects, sustained dosing leads to the kind of neural changes characteristic of other opioid agonists. In other words, the brain adapts to tramadol over time in many of the same ways it adapts to stronger opioids. The process is just slower and sneakier.

A 12-month follow-up comparing abuse rates in patients with chronic pain found that roughly 2.7% of tramadol users scored positive for abuse at least once, compared to 2.5% for NSAIDs and 4.9% for hydrocodone. When more persistent abuse patterns were measured, the rates dropped to 0.7% for tramadol and 1.2% for hydrocodone.⁷ So tramadol’s abuse potential is genuinely lower than that of stronger opioids, but it is not zero, and framing it as “safe” has caused real harm. French surveillance data identified two distinct profiles of high-risk tramadol users: patients originally treated for pain who continued using the drug after the pain resolved, and individuals using it recreationally for its mood-altering effects.⁸

What Happens to Your Body During Extended Use

The health consequences of long-term tramadol use go beyond dependence. Several organ systems are affected, and some of these effects are not widely known even among prescribers.

Hormones and Sexual Health

One of the most consistent findings in long-term tramadol research is a significant drop in testosterone and a rise in prolactin. A prospective controlled study found that these hormonal changes were dose-dependent and worsened as the duration of use increased.⁹ A separate study of tramadol-dependent men found that over half had been using the drug for more than five years, and significant rates of erectile dysfunction and decreased libido were observed compared to controls. Testosterone dropped and prolactin rose as both dose and duration increased, though the hormonal changes appeared to plateau somewhat after five years of use.¹⁰ Animal studies confirm the pattern: after 30 days of tramadol, rats showed decreased levels of luteinizing hormone, follicle-stimulating hormone, and testosterone, along with disrupted testicular tissue.¹¹

These hormonal effects are an opioid-class problem, not unique to tramadol, but they are underappreciated. Many men on long-term tramadol have no idea that their fatigue, low mood, or sexual difficulties could be connected to their painkiller. If you have been taking tramadol for months and notice these symptoms, a simple blood test for testosterone and prolactin can clarify whether the drug is contributing.

Liver Stress and Genetic Vulnerability

Long-term opioid use in general has been linked to liver and kidney changes. An experimental model found that chronic tramadol administration caused liver congestion and focal tissue death, as well as changes to kidney tubular cells.¹² These were animal findings, so direct translation to human risk requires caution, but the direction is consistent with what shows up in human pharmacogenomic data.

Your genetic makeup plays a real role in how much liver damage tramadol can do. The enzyme CYP2D6 is responsible for converting tramadol into its active metabolite, which does most of the opioid-receptor work. People who carry gene variants that make this enzyme work faster (so-called ultra-rapid metabolizers) produce more of that active metabolite, leading to higher levels of oxidative stress and liver damage markers. One study found that ultra-rapid metabolizers developed moderate to severe liver toxicity within about 10 to 11 months of tramadol use, while normal metabolizers took 13 to 16 months to develop milder damage.¹³ The clinical relevance of CYP2D6 variation for tramadol’s pain-relieving effects is well established.¹⁴ What is less often discussed is the flip side: the same genetics that make tramadol work well for pain may also make it more toxic to your liver over time.

Seizure Risk

Tramadol lowers the seizure threshold, and this risk increases with dose. A systematic review and meta-analysis found that at therapeutic doses, the seizure rate was about 3%, while in cases of tramadol poisoning or abuse the rate climbed to roughly 37 to 38%. The odds of seizure were also higher in men.¹⁵ For long-term users, the concern is that gradually escalating doses as tolerance builds can push someone into a higher risk bracket without them realizing it.

Serotonin Syndrome

Because tramadol blocks serotonin reuptake, combining it with antidepressants that also boost serotonin levels can trigger serotonin syndrome, a potentially life-threatening condition involving agitation, high body temperature, muscle rigidity, and rapid heart rate. The combination of tramadol with SSRIs or SNRIs is a recognized risk, and though the incidence is low and usually mild to moderate, severe cases do occur.¹⁶ Long-term users are more likely to accumulate additional prescriptions over time, raising the chance of an interaction that a short-term user might never encounter.

Tramadol and the Aging Brain

A population-based cohort study of older adults with musculoskeletal pain followed participants for up to 14 years and found a dose-response relationship between cumulative tramadol use and dementia risk. Compared to nonusers, people with more than 90 days of cumulative tramadol use had about an 18% higher risk of developing all-cause dementia, and the trend was statistically significant across all duration tiers.¹⁷ This is a single observational study, so it cannot prove causation, and the effect was modest. But it does add a reason for older adults and their doctors to think twice about indefinite tramadol prescriptions, especially when non-opioid alternatives exist.

Separately, a study of older adults with osteoarthritis found that tramadol users generally had fewer adverse events than users of other opioids, but higher risks than people not taking any opioid.¹⁸ That finding neatly captures tramadol’s place in the risk landscape: safer than stronger opioids, but not safe in the way a non-opioid painkiller would be.

When Pain Gets Worse Instead of Better

One of the more paradoxical risks of long-term tramadol use is a phenomenon called opioid-induced hyperalgesia: the drug can actually make you more sensitive to pain. Case reports have documented patients on tramadol who reported worsening, generalized pain that had no apparent medical explanation and that resolved when the drug was tapered off rather than increased.¹⁹ If you have been on tramadol for a while and find that your pain is spreading or that higher doses seem to make things worse rather than better, this is worth raising with your doctor. The instinct to increase the dose is exactly the wrong response.

Why Stopping Tramadol Can Be Unusually Difficult

Withdrawal from long-term tramadol use is complicated by the drug’s dual mechanism. Most cases involve typical opioid withdrawal: muscle aches, sweating, nausea, insomnia, anxiety. But about one in eight cases also involve atypical symptoms not normally seen in opioid withdrawal, including hallucinations, paranoia, extreme anxiety, panic attacks, confusion, and unusual sensory experiences like numbness and tingling.²⁰ These atypical symptoms are thought to result from the sudden loss of tramadol’s effect on serotonin and norepinephrine, essentially creating a withdrawal state similar in some ways to abruptly stopping an antidepressant.²¹

This is one of the most important things long-term users should know: you should not stop tramadol suddenly. Current guidance on opioid tapering recommends gradual dose reductions following a pattern where the cuts get smaller as the total dose decreases, often reducing by roughly 1 to 10% of the most recent dose every one to two weeks, with each step adjusted based on how the person is feeling. For someone who has been on tramadol for years, the tapering process can take many months.²² The final doses before stopping completely need to be very small. Rushing this process is where people get into trouble.

Off-Label Use and Unintended Long-Term Exposure

Some people end up on tramadol long-term not because of chronic pain but because of an off-label use that extends beyond what was originally intended. One of the more common off-label applications is for premature ejaculation. A study of 300 men given tramadol at doses of 25, 50, or 100 mg for 24 weeks found significant improvements in ejaculatory latency time across all dose groups.²³ The serotonin reuptake effects that make tramadol work for this purpose also mean that stopping the drug brings back the original problem, creating a cycle that can quietly turn a short-term fix into years of daily use. This pathway to long-term exposure is particularly concerning because it often happens outside the monitoring framework that chronic-pain patients receive.

The Regulatory Backdrop

Tramadol was not classified as a controlled substance in the United States until August 2014, decades after it entered the market. When federal restrictions were placed on tramadol, prescribing did begin to decline, with an estimated 4% yearly decrease in use since 2014.²⁴ But the scheduling change had an unintended side effect: tightening restrictions on one opioid simply shifted prescribing toward close substitutes, resulting in no net reduction in total opioid prescriptions.²⁵ The lesson is that tramadol’s regulatory history reflects a decades-long underestimation of its risks, and the correction has been only partly effective.

Common Side Effects That Accumulate

Short-term tramadol use comes with a familiar list of side effects: nausea, dizziness, constipation, and vomiting are the most frequently reported, even in controlled trial settings using extended-release formulations combined with acetaminophen.²⁶ With long-term use, these do not necessarily go away. Constipation in particular tends to persist and worsen, and chronic opioid-induced constipation can itself lead to further complications. The cumulative burden of “minor” side effects is something that often gets overlooked when the conversation focuses on more dramatic risks like dependence or seizures, but it matters to quality of life. People who have been tolerating daily nausea or constipation for months sometimes do not even connect it to their tramadol prescription anymore.

Depression is another consequence that has received increasing attention. The retrospective cohort study mentioned earlier found that patients with 90 or more cumulative days of tramadol use faced a higher risk of depression compared to those with shorter exposure.² This is a tricky finding because chronic pain itself causes depression, and disentangling the two is methodologically difficult. Still, the possibility that a drug with serotonin-modulating properties could, over time, disrupt mood regulation rather than support it is biologically plausible and worth keeping in mind.

Who Metabolizes Tramadol Differently

Not everyone processes tramadol at the same speed, and the differences are not small. CYP2D6, the liver enzyme responsible for converting tramadol into its more potent active form, comes in several genetic variants. Poor metabolizers get less pain relief from tramadol because they produce less of the active metabolite. Ultra-rapid metabolizers get more pain relief but also face a higher risk of side effects and, as the hepatotoxicity data shows, faster organ damage with long-term use.¹³ The proportion of ultra-rapid metabolizers varies by ethnicity, with some populations having rates as high as 10% or more. If you are an ultra-rapid metabolizer and no one has told you, you could be accumulating liver damage without obvious early warning signs. Pharmacogenomic testing is available but rarely ordered before starting tramadol. Given that the drug was long considered low-risk, the gap between what we know about genetic variability and how that knowledge is applied in practice remains wide.